Skip to content

Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma

Therapeutic Recommendations for Children Registered in the RFAOP Register and With a Hodgkin Lymphoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05407480
Acronym
GFAOPLH2019
Enrollment
250
Registered
2022-06-07
Start date
2022-11-15
Completion date
2030-12-31
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Staging, Therapeutic Recommendations

Brief summary

The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data. Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.

Detailed description

In high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. Within the same country, there are also differences between the therapeutic protocols used in the different centres. The Experience of Sub-Saharan African Units of the Franco-African Paediatric Oncology Group (GFAOP) in the treatment of pediatric Hodgkin lymphoma in 104 patients was based on chemotherapy alone. The latter was based on COPP/ABV cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. Overall survival at 5 years was 82% at 30 months after a median decrease of 17 months. It seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the African countries. So with this recommendation the GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data. \- Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.

Interventions

OTHERObservational

Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome

Sponsors

French Africa Pediatric Oncology Group
Lead SponsorOTHER
Gustave Roussy, Cancer Campus, Grand Paris
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Months to 18 Years

Inclusion criteria

under 18 years of age at diagnosis * suffering from "classical" Hodgkin's disease according to the WHO classification. * with no history of hematological malignancies or constitutional or acquired immune deficiencies

Exclusion criteria

* Over 18 years of age at diagnosis * A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies

Design outcomes

Primary

MeasureTime frameDescription
Patient status24 monthsDead or Alive
Drugs24 monthsThe evaluation of the number of children who remain untreated because of lack of acess to chemotherapy

Countries

France

Contacts

CONTACTBrenda MS MALLON
brenda.mallon@gustaveroussy.fr0033 142115411
CONTACTFATEN Ben Ayed, Professeur
faten.fedhila@yahoo.fr
PRINCIPAL_INVESTIGATORFATEN Ben Ayed, Professeur

French Africa Pediatric Oncology Group

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026